ASTHERNA is a RNA therapy company developing a treatment for Stargardt disease, an inherited progressive retinal disorder, affecting hundred thousand individuals worldwide. For several genetic defects that cause this disease, we have developed a unique therapeutic approach with which we aim to stop the progression of the disease, and prevent individuals from getting blind. Astherna aims to develop therapeutic molecules, demonstrate efficacy and safety, in order to maximize the impact of our therapeutic solution on patient’s lives.
“I am diagnosed with Stargardt disease.
Without any treatment, I will lose my vision,
and this greatly impacts my life.”
Lotte, 21 years old
Prof. dr. Rob W.J. Collin
Inventor, Founder & CSO
Prof. dr. Carel B. Hoyng
Founder & COO
Dr. Corné H. van den Kieboom